SANA
Sana Biotechnology, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$2.57Close
$685.5MMarket cap
$2.27 – $5.1852-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 8 · weaker than 92% of stocks over 12 months
- Far from its high 50% below its 52-week high
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
50%
1wk
up 10.3%
price change
1mo
down 11.8%
price change
12-month return
down 48%
market up 11% ·
its own down 63%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.3×
price / book
Earnings yield
down 40.8%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 119%
return on equity
Free cash margin
—
-$144.8M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.8%
$0.17 a day · 2×ATR $2.22
RS
8 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.63
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 19.1% over the year, from 224m to 267m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026+8% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$286.1M | -$356.9M | -$272.6M | -$293.1M | -$272.7M | -$250.3M |
| Net income | -$285.3M | -$355.9M | -$269.5M | -$283.3M | -$266.8M | -$244.2M |
| Earnings per share | -$21.92 | -$2.14 | -$1.43 | -$1.46 | -$1.16 | -$0.96 |
| Free cash flow | -$161.9M | -$280.9M | -$310.9M | -$273.6M | -$256.6M | -$144.8M |
| Cash | $124.8M | $253.0M | $176.8M | $133.5M | $127.6M | $71.9M |
| Shareholders' equity | -$421.2M | $728.5M | $499.3M | $287.5M | $250.5M | $160.9M |
| Shares outstanding | 16.17m | 184.93m | 191.02m | 197.86m | 223.92m | 266.73m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 11, 2026 | Quarterly ↗ | Mar 31, 2026 | 41d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 17, 2025 | Annual ↗ | Dec 31, 2024 | 76d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 8, 2026 | Regulation FD ↗ |
| Aug 10, 2026 | Results ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| May 15, 2026 | Other events ↗ |
| May 11, 2026 | Results ↗ |
| Apr 24, 2026 | Director or officer change ↗ |
| Apr 13, 2026 | Other events ↗ |
| Mar 3, 2026 | Results · Other events ↗ |
| Feb 17, 2026 | Director or officer change · Regulation FD ↗ |
| Jan 14, 2026 | Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Sep 5, 2025 | Director or officer change · Other events ↗ |